These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8709674)

  • 1. [Profitability of hypolipidemic drug treatment].
    Gérvas J; Pérez Fernández M
    Med Clin (Barc); 1996 Jun; 107(1):37-8. PubMed ID: 8709674
    [No Abstract]   [Full Text] [Related]  

  • 2. [Profitability of hypolipidemic drug treatments].
    Subías Lorén PJ; Ginés García C
    Med Clin (Barc); 1996 Jun; 107(1):37. PubMed ID: 8709673
    [No Abstract]   [Full Text] [Related]  

  • 3. [Medical cost of cardiovascular risk factors prevention in France].
    Marques-Vidal P; Bongard V; Arveiler D; Amouyel P; Ducimetière P; Ferrières J
    Arch Mal Coeur Vaiss; 2002 Apr; 95(4):275-81. PubMed ID: 12055766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypercholesterolemia, cardiovascular risk, and hypocholesteremic treatment in the elderly].
    Cicconetti P; Ciotti V; Tafaro L; Riolo N; Marigliano V
    Recenti Prog Med; 2002 Apr; 93(4):264-72. PubMed ID: 11989134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost of cardiovascular risk factor prevention in middle-aged French men. The PRIME study].
    Marques-Vidal P; Arveiler D; Amouyel P; Ducimetière P; Ferrières J
    Rev Epidemiol Sante Publique; 2001 Dec; 49(6):541-9. PubMed ID: 11845103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of hypercholesterolemia in the elderly].
    Mulder WJ; Lavrijssen AT; Wolffenbuttel BH; Fiolet JF
    Ned Tijdschr Geneeskd; 1995 Apr; 139(16):821-5. PubMed ID: 7731473
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug treatment and cost of cardiovascular disease in Australia.
    Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
    Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol reduction: what can we afford?
    Luepker RV
    Eur Heart J; 2001 May; 22(9):720-1. PubMed ID: 11350101
    [No Abstract]   [Full Text] [Related]  

  • 9. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.
    Fodor JG; Frohlich JJ; Genest JJ; McPherson PR
    CMAJ; 2000 May; 162(10):1441-7. PubMed ID: 10834048
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparison of coronary risk estimates derived using the Framingham and REGICOR equations].
    Cristóbal J; Lago F; de la Fuente J; González-Juanatey JR; Vázquez-Bellés P; Vila M
    Rev Esp Cardiol; 2005 Aug; 58(8):910-5. PubMed ID: 16053824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Controversies and advances in the treatment of hyperlipidemias].
    Reza-Albarrán A; Aguilar-Salinas CA
    Gac Med Mex; 1998; 134(2):253-6. PubMed ID: 9619005
    [No Abstract]   [Full Text] [Related]  

  • 12. [Medical recommendations and references about hypolipidemic drugs. ANDEM (National Agency for the Development of Medical Evaluation].
    J Mal Vasc; 1997 Oct; 22(4):249-64. PubMed ID: 9411011
    [No Abstract]   [Full Text] [Related]  

  • 13. [Total cardiovascular risk. When is a medication prophylaxis meaningful].
    Einecke D
    MMW Fortschr Med; 2003 Oct; 145(44):6-8. PubMed ID: 14655495
    [No Abstract]   [Full Text] [Related]  

  • 14. [Decisions regarding cholesterol-lowering therapy in the elderly: the experience in a lipid clinic and a review of the literature].
    Garrido Sanjuán JA; Pía Iglesias G; González Moraleja J; Sesma P
    An Med Interna; 1998 Jun; 15(6):305-10. PubMed ID: 9656510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of diabetes as a cardiovascular risk factor.
    Plouin PF
    Int J Clin Pract Suppl; 2000 May; (110):3-8. PubMed ID: 10912301
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hypercholesterolemia as cardiovascular risk in hypertensive patients. Therapeutic implications: efficiency of statins].
    Borghi C; Veronesi M
    Recenti Prog Med; 2003 Oct; 94(10):421-6. PubMed ID: 14619187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment].
    Buitrago F; Cañón-Barroso L; Díaz-Herrera N; Cruces-Muro E; Escobar-Fernández M; Serrano-Arias JM
    Rev Esp Cardiol; 2007 Feb; 60(2):139-47. PubMed ID: 17338879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intestinal cholesterol absorption: a pharmacological target for lowering of plasma cholesterol].
    Catapano AL; Catapano L; Fellin R
    Ital Heart J Suppl; 2004 Oct; 5(10):779-84. PubMed ID: 15615349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care].
    Jancsó Z; Varga Z; Simay A; Ilyés I
    Orv Hetil; 2005 Dec; 146(52):2629-33. PubMed ID: 16468604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Statins in practice of the vascular surgeon and cardiologist].
    Pokrovskiĭ AV; Suntsov DS
    Angiol Sosud Khir; 2009; 15(2):123-7. PubMed ID: 19806952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.